Do analysts recommend ZIVO or LONA?

Athira Pharma has a consensus target price of $17.33, indicating a potential upside of 116.40%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ZIVO or LONA more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Athira Pharma N/A -411.58% -225.73%

Do analysts recommend SPRO or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ZIVO or MNOV?

MediciNova has a consensus price target of $8.33, indicating a potential upside of 430.79%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts prefer ZIVO or TENX?

Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 503.45%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenax Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56

Is ZIVO or TENX more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Tenax Therapeutics N/A -61.54% -57.42%

Do analysts recommend TLPH or ZIVO?

Talphera currently has a consensus target price of $3.00, indicating a potential upside of 143.90%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Talphera is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TLPH or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% ZIVO Bioscience N/A N/A -2,240.92%

ZIVO Bioscience (ZIVO) Competitors

$4.27 0.00 (0.00%)

As of 08/24/2026 02:56 PM Eastern

Compare

ZIVO vs. LONA, SPRO, MNOV, TENX, and TLPH

Should you buy ZIVO Bioscience stock or one of its competitors? ZIVO Bioscience's main competitors and comparable companies include Athira Pharma (LONA), Spero Therapeutics (SPRO), MediciNova (MNOV), Tenax Therapeutics (TENX), and Talphera (TLPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ZIVO Bioscience compare to Athira Pharma?

ZIVO Bioscience (NASDAQ:ZIVO) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

ZIVO Bioscience's return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Athira Pharma	N/A	-411.58%	-225.73%

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 25.7% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Athira Pharma had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Athira Pharma and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.00 beat Athira Pharma's score of -0.65 indicating that ZIVO Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Athira Pharma	Negative

Athira Pharma has a consensus target price of $17.33, indicating a potential upside of 116.40%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

ZIVO Bioscience has higher revenue and earnings than Athira Pharma. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,135.52	-$7.78M	-$1.40	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

ZIVO Bioscience has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Summary

ZIVO Bioscience and Athira Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Spero Therapeutics has a net margin of 24.90% compared to ZIVO Bioscience's net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat ZIVO Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
ZIVO Bioscience	N/A	N/A	-2,240.92%

In the previous week, Spero Therapeutics had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Spero Therapeutics and 0 mentions for ZIVO Bioscience. Spero Therapeutics' average media sentiment score of 0.86 beat ZIVO Bioscience's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Positive
ZIVO Bioscience	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Spero Therapeutics has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.07	$8.57M	$0.11	11.18
ZIVO Bioscience	$15.85K	1,135.52	-$7.78M	-$1.40	N/A

Spero Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.14, meaning that its stock price is 86% less volatile than the broader market.

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Spero Therapeutics beats ZIVO Bioscience on 12 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to MediciNova?

ZIVO Bioscience (NASDAQ:ZIVO) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

MediciNova has a consensus price target of $8.33, indicating a potential upside of 430.79%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

ZIVO Bioscience has higher earnings, but lower revenue than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,135.52	-$7.78M	-$1.40	N/A
MediciNova	$410K	188.48	-$12M	-$0.21	N/A

ZIVO Bioscience has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. ZIVO Bioscience's return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
MediciNova	-1,168.70%	-26.51%	-24.39%

ZIVO Bioscience has a beta of 0.14, meaning that its share price is 86% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, MediciNova had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for MediciNova and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.00 beat MediciNova's score of -0.15 indicating that ZIVO Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
MediciNova	Neutral

Summary

MediciNova beats ZIVO Bioscience on 9 of the 17 factors compared between the two stocks.

How does ZIVO Bioscience compare to Tenax Therapeutics?

ZIVO Bioscience (NASDAQ:ZIVO) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 503.45%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

ZIVO Bioscience has a beta of 0.14, meaning that its stock price is 86% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

ZIVO Bioscience has higher revenue and earnings than Tenax Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,135.52	-$7.78M	-$1.40	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

ZIVO Bioscience's return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Tenax Therapeutics	N/A	-61.54%	-57.42%

In the previous week, Tenax Therapeutics had 10 more articles in the media than ZIVO Bioscience. MarketBeat recorded 10 mentions for Tenax Therapeutics and 0 mentions for ZIVO Bioscience. Tenax Therapeutics' average media sentiment score of 1.71 beat ZIVO Bioscience's score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Tenax Therapeutics	Very Positive

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Tenax Therapeutics beats ZIVO Bioscience on 8 of the 15 factors compared between the two stocks.

How does ZIVO Bioscience compare to Talphera?

Talphera (NASDAQ:TLPH) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Talphera currently has a consensus target price of $3.00, indicating a potential upside of 143.90%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Talphera is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

37.7% of Talphera shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ZIVO Bioscience's return on equity of 0.00% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
ZIVO Bioscience	N/A	N/A	-2,240.92%

In the previous week, Talphera had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Talphera and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.00 beat Talphera's score of -0.29 indicating that ZIVO Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Neutral
ZIVO Bioscience	Neutral

Talphera has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.14, meaning that its share price is 86% less volatile than the broader market.

ZIVO Bioscience has lower revenue, but higher earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	2,128.31	-$14.29M	-$0.27	N/A
ZIVO Bioscience	$15.85K	1,135.52	-$7.78M	-$1.40	N/A

Summary

Talphera beats ZIVO Bioscience on 10 of the 15 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZIVO vs. The Competition

Export

Metric	ZIVO Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.00M	$12.54B	$7.35B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	11.02%
P/E Ratio	-0.87	778.14	270.96	24.14
Price / Sales	1,135.52	754.40	634.76	101.59
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	-5.27	12.02	13.14	6.25
Net Income	-$7.78M	$2.80B	$3.46B	$347.86M
7 Day Performance	8.10%	2.88%	1.52%	0.98%
1 Month Performance	-14.60%	6.55%	8.82%	5.24%
1 Year Performance	-77.54%	8.09%	26.08%	17.04%

ZIVO Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZIVO ZIVO Bioscience	N/A	$4.27 flat	N/A	-76.3%	$18.00M	$15.85K	N/A	10	Upcoming Earnings
LONA Athira Pharma	3.1143 of 5 stars	$7.71 +0.1%	$17.33 +124.8%	N/A	$72.43M	N/A	N/A	40
SPRO Spero Therapeutics	1.7185 of 5 stars	$1.23 +1.2%	N/A	-33.5%	$71.34M	$42.96M	11.14	150
MNOV MediciNova	1.8801 of 5 stars	$1.40 +1.8%	$8.33 +497.4%	+18.9%	$68.66M	$410K	N/A	10
TENX Tenax Therapeutics	4.2146 of 5 stars	$1.74 -2.2%	$14.00 +704.6%	-60.8%	$65.11M	N/A	N/A	9	Positive News Insider Trade Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. LONA, SPRO, MNOV, TENX, and TLPH

How does ZIVO Bioscience compare to Athira Pharma?

Summary

How does ZIVO Bioscience compare to Spero Therapeutics?

Summary

How does ZIVO Bioscience compare to MediciNova?

Summary

How does ZIVO Bioscience compare to Tenax Therapeutics?

Summary

How does ZIVO Bioscience compare to Talphera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. LONA, SPRO, MNOV, TENX, and TLPH

How does ZIVO Bioscience compare to Athira Pharma?

Is ZIVO or LONA more profitable?

Do institutionals and insiders have more ownership in ZIVO or LONA?

Does the media favor ZIVO or LONA?

Do analysts recommend ZIVO or LONA?

Which has stronger earnings & valuation, ZIVO or LONA?

Which has more risk & volatility, ZIVO or LONA?

Summary

How does ZIVO Bioscience compare to Spero Therapeutics?

Is SPRO or ZIVO more profitable?

Does the media prefer SPRO or ZIVO?

Do analysts recommend SPRO or ZIVO?

Which has preferable earnings & valuation, SPRO or ZIVO?

Which has more risk and volatility, SPRO or ZIVO?

Do institutionals & insiders believe in SPRO or ZIVO?

Summary

How does ZIVO Bioscience compare to MediciNova?

Do analysts recommend ZIVO or MNOV?

Which has stronger valuation & earnings, ZIVO or MNOV?

Is ZIVO or MNOV more profitable?

Which has more volatility and risk, ZIVO or MNOV?

Do institutionals and insiders believe in ZIVO or MNOV?

Does the media prefer ZIVO or MNOV?

Summary

How does ZIVO Bioscience compare to Tenax Therapeutics?

Do analysts prefer ZIVO or TENX?

Which has more volatility & risk, ZIVO or TENX?

Which has higher valuation & earnings, ZIVO or TENX?

Is ZIVO or TENX more profitable?

Does the media favor ZIVO or TENX?

Do institutionals & insiders hold more shares of ZIVO or TENX?

Summary

How does ZIVO Bioscience compare to Talphera?

Do analysts recommend TLPH or ZIVO?

Do insiders & institutionals have more ownership in TLPH or ZIVO?

Is TLPH or ZIVO more profitable?

Does the media refer more to TLPH or ZIVO?

Which has more risk & volatility, TLPH or ZIVO?

Which has preferable valuation & earnings, TLPH or ZIVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools